Do you know the ACT-EU initiative?
Accelerating Clinical Trials in the EU (ACT-EU), launched in January 2022 with the collaboration of European Commission, the European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) and driven by the implementation of the Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 and the CTIS system. This initiative aims to accelerate and promote quality and innovative clinical research to deliver safe and effective treatments for patients.
It will promote and support sponsors to be able to conduct larger, faster and multinational clinical studies. Stakeholder engagement will be essential to share knowledge and feedback through its platform to amplify the impact of European clinical trials and position ourselves in a unified global manner.
For more information, visit ACT-EU’s action plan and priority action areas:
Or participate in its multi-stakeholder methodology workshops: